Antiplasmodial Activity and Pharmacokinetic Profiling of Cryptolepine and 2,7‐Dibromocryptolepine With a View to Informing the Design of Novel Antimalarial Cryptolepine Analogues
Open Access
- 3 February 2026
- journal article
- Published by Wiley in Drug Development Research
- Vol. 87 (2) , e70245
Abstract
The roots of the climbing shrub Cryptolepis sanguinolenta are traditionally used in West Africa for the treatment of malaria. The principal constituent, cryptolepine ( 1 ), has been shown to have antimalarial activity but there are concerns regarding its toxicity on account of its DNA‐intercalating property. The synthetic analogue, 2,7‐dibromocryptolepine, ( 2 ) does not intercalate into DNA and is markedly more active than the parent against Plasmodium sp. in vitro and in vivo. The aim of this study was to carry out a pre‐clinical assessment of 1 and 2 , and if appropriate, carry out in vivo pharmacokinetic studies. Cryptolepine ( 1 ) and 2,7‐dibromocryptolepine ( 2 ), were evaluated in a range of in vitro assays in line with those recommended by Medicines for Malaria Venture (MMV) for the profiling of a Validated Hit Compound ( https://www.mmv.org/frontrunner-templates ). In vitro profiling of 1 and 2 showed that 2 is superior to 1 with respect to antiplasmodial activities, and the parasite rate of kill (fast for 2 , in contrast with modest for 1 ); however 2 exhibited potent inhibition of the hERG potassium channel, (IC 50 = 1.0 µM compared with 7.8 µM for 1 ), raising concerns that 2 may be cardiotoxic, so that 2 was not selected for in vivo pharmacokinetic profiling. The studies of cryptolepine ( 1 ) pharmacokinetics in the rat revealed a second peak, especially with oral administration, indicating that enterohepatic circulation following biliary excretion may be taking place. This study complements previous pharmacokinetic data of 1 and presents novel data on 2,7‐dibromocryptolepine ( 2 ) that will inform the development of cryptolepine analogues as potential antimalarial agents.Keywords
Funding Information
- Bill and Melinda Gates Foundation
- Medicines for Malaria Venture
This publication has 21 references indexed in Scilit:
- Thousands of chemical starting points for antimalarial lead identificationNature, 2010
- Synthesis of Some Cryptolepine Analogues, Assessment of Their Antimalarial and Cytotoxic Activities, and Consideration of Their Antimalarial Mode of ActionJournal of Medicinal Chemistry, 2005
- In vitro genotoxicity of the West African anti-malarial herbal Cryptolepis sanguinolenta and its major alkaloid cryptolepineToxicology, 2005
- Substrate SARs in human P450sDrug Discovery Today, 2002
- The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sitesNature Structural & Molecular Biology, 2001
- Synthesis and Evaluation of Cryptolepine Analogues for Their Potential as New Antimalarial AgentsJournal of Medicinal Chemistry, 2001
- Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosisEuropean Journal of Pharmacology, 2000
- Isolation and Unambiguous Synthesis of Cryptolepinone: An Oxidation Artifact of CryptolepineJournal of Natural Products, 1998
- In Vitro and in Vivo Antiplasmodial Activity of Cryptolepine and Related Alkaloids from Cryptolepis sanguinolentaJournal of Natural Products, 1997
- Biliary Excretion of Quaternary Ammonium Compounds and Tertiary Amines in the RatActa Pharmacologica et Toxicologica, 1971